Fed Circuit reverses Novartis’ drug patent win

23-06-2022

Fed Circuit reverses Novartis’ drug patent win

Taljat David / Shutterstock.com

The US Court of Appeals for the Federal Circuit has held that a patent covering Novartis’ multiple sclerosis drug Gilenya is invalid, potentially opening the floodgates for the introduction of generic versions of the drug. 


Novartis, Federal Circuit, patent, patent infringement, HEC Pharm, Gilenya, generics, multiple sclerosis, US: generics, big pharma

LSIPR